Pancreatic Cancer Research

ResearcherQingdao UniversityActive in the last 2 years

Yumin Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9267-1412; OpenAlex author ID A5100630384, A5121928040. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 14

  1. Integrin α5β1 in pancreatic ductal adenocarcinoma: Tumour‒stroma crosstalk, hypoxia and therapeutic targeting. Last author DOI 10.1002/ctm2.70759↗
  2. Repurposing dronedarone induces ferroptosis through GPX4 inactivation and degradation in pancreatic cancer. Last author DOI 10.1186/s13046-026-03687-6↗
  3. Development and validation of a nomogram for a prognostic model for resected pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hbpd.2025.04.005↗
  4. Update on the global, regional, and national burden of pancreatic cancer: Insights from the Global Burden of Disease 2021 Study. Last author DOI 10.1097/cm9.0000000000003753↗
  5. The dual role of gut microbiota in pancreatic cancer: new insights into onset and treatment. Last author DOI 10.1177/17588359251324882↗
  6. YWHAG acts as a prognostic marker and is correlated with immune infiltration and cell metastasis in pancreatic cancer Last author DOI 10.21203/rs.3.rs-3447681/v1↗
  7. Construction of targeted 10B delivery agents and their uptake in gastric and pancreatic cancer cells. Last author DOI 10.3389/fonc.2023.1105472↗
  8. 18F-labeled Dimer-Sansalvamide A Cyclodecapeptide: A Novel Diagnostic Probe to Discriminate Pancreatic Cancer from Inflammation in a Nude Mice Model. Last author DOI 10.7150/jca.69710↗
  9. Survival Benefit of Metformin Use for Pancreatic Cancer Patients Who Underwent Pancreatectomy: Results From a Meta-Analysis. Last author DOI 10.3389/fmed.2020.00282↗
  10. Prediction of therapeutic outcome and survival in a transgenic mouse model of pancreatic ductal adenocarcinoma treated with dendritic cell vaccination or CDK i… Co-author PMID 32509212↗
  11. Clinical effect and safety of dendritic cell-cytokine-induced killer cell immunotherapy for pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.1016/j.jcyt.2019.07.006↗
  12. PET imaging of Hsp90 expression in pancreatic cancer using a new 64Cu-labeled dimeric Sansalvamide A decapeptide. Co-author DOI 10.1007/s00726-018-2566-y↗
  13. Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: A pooled analysis. Last author DOI 10.1016/j.pan.2016.09.015↗
  14. LRH1 promotes pancreatic cancer metastasis. Co-author DOI 10.1016/j.canlet.2014.04.017↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huijuan Cheng · 3 shared papers, 2025 · strength 0.91
  2. Chenzhe Ma · 2 shared papers, 2026 · strength 0.80
  3. Hao Hui Chen · 2 shared papers, 2025 · strength 0.60
  4. Yanmei Gu · 1 shared paper, 2026 · strength 0.30
  5. Jun Zhang · 2 shared papers, 2018–2022 · strength 0.30
  6. Xiaohui Wang · 2 shared papers, 2018–2022 · strength 0.30
  7. Tianliang Song · 1 shared paper, 2025 · strength 0.24
  8. Wenzhi Guo · 1 shared paper, 2025 · strength 0.24
  9. Daijun Wang · 1 shared paper, 2024 · strength 0.23
  10. Muzhou Teng · 1 shared paper, 2023 · strength 0.20
  11. Song Wang · 1 shared paper, 2023 · strength 0.20
  12. Junqiang Zhang · 1 shared paper, 2020 · strength 0.13
  13. Jichun Ma · 1 shared paper, 2020 · strength 0.13
  14. Zuoyi Jiao · 1 shared paper, 2020 · strength 0.13
  15. Vahid Yaghmai · 1 shared paper, 2020 · strength 0.11
  16. Su Hu · 1 shared paper, 2020 · strength 0.11
  17. Jia Ying Yang · 1 shared paper, 2020 · strength 0.11
  18. Aydın Eresen · 1 shared paper, 2020 · strength 0.11
  19. Zhuoli Zhang · 1 shared paper, 2020 · strength 0.11
  20. Al B. Benson · 1 shared paper, 2020 · strength 0.11
  21. Kai Chen · 1 shared paper, 2018 · strength 0.10
  22. Yali Liu · 1 shared paper, 2019 · strength 0.10
  23. Xiaoying Si · 1 shared paper, 2016 · strength 0.08
  24. Yanming Zhou · 1 shared paper, 2016 · strength 0.08
  25. Shaofan Weng · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.